^
Association details:
| Biomarker: | CD74-ROS1 D2033N fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer
Excerpt:
A 50 year-old female never smoker with metastatic lung adenocarcinoma...To identify molecular mechanism(s) of crizotinib-resistance, we analyzed a biopsy from a growing retroperitoneal lymph node after progression on crizotinib using NGS that confirmed persistent expression of the CD74-ROS1 rearrangement...deep-sequencing also revealed the acquisition of a novel mutation, ROS1 D2033N...
DOI:
10.1158/1078-0432.CCR-15-2013
